Bank of New York Mellon’s Elicio Therapeutics ELTX Stock Holding History

Bank of New York Mellon’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$62.1K	Buy	+15,884	New	+$159K	﹤0.01%	4226
2022 Q2	–	Sell	-4,309	Closed	-$91K	–	4621
2022 Q1	$91K	Hold	4,309	–	–	﹤0.01%	4423
2021 Q4	$125K	Buy	4,309 +120	+3%	+$6.07K	﹤0.01%	4370
2021 Q3	$409K	Buy	+4,189	New	+$453K	﹤0.01%	3914
2021 Q2	–	Sell	-1,042	Closed	-$188K	–	4412
2021 Q1	$188K	Buy	+1,042	New	+$201K	﹤0.01%	4069

Other funds holding ELTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSA

Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

MHC

Meyer Handelman Company Rye Brook, New York $3.53B AUM 30.49% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's ELTX Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 15,884 shares worth $62.1K. The stake represents ﹤0.01% of the portfolio and ranks #4226 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in ELTX as recently as Q1 2022.

Bank of New York Mellon first reported a position in ELTX in Q1 2021 and has held it in 5 quarters since. The position peaked at $409K in Q3 2021. 25 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Bank of New York Mellon held 15,884 shares of Elicio Therapeutics worth $62.1K as of Q2 2026.
Elicio Therapeutics was a new Bank of New York Mellon position in Q2 2026.
Elicio Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4226 holding.
Bank of New York Mellon first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 5 quarters since.
Bank of New York Mellon's Elicio Therapeutics position peaked at $409K in Q3 2021.
25 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.